The nation of Zimbabwe has turned down a substantial American health deal valued at $367m (£272m) over five years due to Washington's request for confidential information.
This move became public after a official document dated December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesman has since explained that the United States was seeking genetic material for scientific study and commercial purposes but was not willing to share the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued talks to secure a agreement agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Wider Context
This development follows a comparable case in Kenya, where a high court halted a related health funding agreement following concerns were filed about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
According to reports, Sixteen nations in Africa have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Details of the Declined Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would provide the basic resources for medical research with no certainty that the end products would be accessible to our people if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending systems already established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to deal with future pandemics.
"This mechanism is intended to guarantee that when a country provides its data, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage continued dialogue with our American counterparts on how future collaboration might be structured in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts expressed it recognised the government's concerns, but suggested that talks should continue given that much of the country's Aids initiatives relied on international support.
"Where technical issues exist, such as those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group commented.
The situation underscores the ongoing debate between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.